Related Experiment Video
Updated: Aug 14, 2026
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Immunotherapy with imiquimod 5% cream for eyelid nodular basal cell carcinoma
Maria Antonietta Blasi1, Daniele Giammaria, Emilio Balestrazzi
1Department of Ophthalmology, University of L'Aquila, Ospedale San Salvatore, 67100 L'Aquila, Italy. ma.blasi@flashnet.it
Purpose:
To evaluate the efficacy and safety of topical imiquimod 5% cream for the treatment of eyelid basal cell carcinoma.
Design:
Two interventional case reports.
Methods:
Imiquimod 5% cream was applied topically once daily, 3 days a week for 8 to 12 weeks, in two patients affected by eyelid nodular basal cell carcinoma. Patients were followed up clinically with slit-lamp examination for evidence of tumor disappearance or recurrence, and local and systemic side effects.
Results:
Complete clinical response was obtained in both patients. No severe local side effects were observed. Patients did not show any local recurrence after 1 year.
Conclusions:
Topical imiquimod 5% cream seems to be a useful treatment for eyelid nodular basal cell carcinoma in selected cases, but further long-term studies are needed to assess the efficacy and safety of this approach.
Related Concept Videos
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
01:27Tumor Immunotherapy